EGFR and non-small cell lung carcinoma: Furthermore, CK2 inhibition with CX-4945 has proven synergistic with chemotherapy or erlotinib in non-oncogene-driven and EGFR mutant NSCLC, respectively, by attenuating the PI3K-Akt pathway [46,47].